CG Oncology, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CG Oncology, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($43.81M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($41.43M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($41.43M) | Aug 8, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($34.45M) | Nov 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($34.45M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($34.45M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($20.41M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($18.90M) | Aug 8, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($18.90M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($16.93M) | May 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($16.93M) | Aug 8, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($16.93M) | Nov 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($11.77M) | Nov 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($11.61M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($11.61M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($8.67M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($8.67M) | Aug 8, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($8.67M) | Nov 12, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($51.13M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($48.74M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($42.20M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($28.30M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($25.85M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($22.47M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($14.04M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($12.33M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($9.72M) | May 9, 2024 |